A study demonstrated that pre-transplant measurable residual disease (MRD) status is a strong prognostic factor for overall ...

Mesoblast stock climbs 80% in a month following the FDA's approval of Ryoncil as the only approved therapy for SR-aGVHD in children aged two months and older.

Mesoblast’s achievement in winning approval for its Ryoncil drug in the US in December heralds the arrival of a new class of ...

A phase 3 trial confirms “the potent anti-leukemic effect” of consolidation with allogeneic transplant in older patients with acute myeloid leukemia, according to researchers.

Dorocubicel is under clinical development by ExCellThera and currently in Phase II for Blood Cancer. According to GlobalData, Phase II drugs for Blood Cancer have a 34% phase transition success rate ...

The regulator has cleared Ryoncil (remestemcel-L) to treat steroid-refractory acute GVHD in paediatric patients aged two months and older. It is derived from MSCs harvested from the bone marrow of ...

In the 132-patient ROCKstar study, almost three quarters of chronic GVHD patients treated with a daily oral dose of belumosudil (KD025) saw an improvement in symptoms that lasted for at least six ...

Pimicotinib hydrochloride is under clinical development by Abbisko Therapeutics and currently in Phase I for Pancreatic Cancer.

On December 20, 2024, the FDA granted accelerated approval to the combination of encorafenib (Braftovi), cetuximab (Erbitux), ...

Let’s cover six scientifically backed methods to address the post-stem cell transplant procedure side effects you may be experiencing.